Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update – NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – First Quarter 2026 Financial Highlights Cash, cash equivalents and investments were $646.1 million as of March 31, 2026, compared to $656.6 million as of December 31, 2025. The Company believes that its current cash, cash equivalents and investments will be sufficient to fund its pl ...